Salt Lake City, UT-based biotech company Microvascular Therapeutics said that its echocardiography contrast agent MVT-100 (CardiSon) performed well in a phase II clinical trial.
In the study, 16 subjects received injections of either the predicate agent Perflutren or CardiSon at four different dose levels prior to echocardiographic imaging, which was performed at three different time-points after injection. Three cardiologists, blinded to which agent was administered, then evaluated the images based on visualizing the borders of the left ventricle of the heart and the presence or absence of shadowing.
“CardiSon provided statistically significant better contrast enhancement on the study as well as minimal shadowing. The safety and laboratory parameters from the study indicated that both CardiSon and Perflutren were safe,” said one of the study leads, Elizabeth Krupinski, PhD, of Emory University, in a news release.
The study suggests that CardiSon will provide contrast over a wide range of doses and help avoid shadowing, which can be seen with some agents at higher doses, added the company’s founder and chief executive officer, Evan Unger, MD.
